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Dysregulation of bile acids increases the risk for
preterm birth in pregnant women
Sangmin You1,4, Ai-Min Cui2,4, Syed F. Hashmi1,4, Xinmu Zhang1, Christina Nadolny1, Yuan Chen1, Qiwen Chen1,
Xin Bush1, Zachary Hurd1, Winifer Ali1, Gang Qin 3 & Ruitang Deng 1✉
Preterm birth (PTB) is the leading cause of perinatal mortality and newborn complications.
Bile acids are recognized as signaling molecules regulating a myriad of cellular and metabolic
activities but have not been etiologically linked to PTB. In this study, a hospital-based cohort
study with 36,755 pregnant women is conducted. We find that serum total bile acid levels
directly correlate with the PTB rates regardless of the characteristics of the subjects and
etiologies of liver disorders. Consistent with the findings from pregnant women, PTB is
successfully reproduced in mice with liver injuries and dysregulated bile acids. More
importantly, bile acids dose-dependently induce PTB with minimal hepatotoxicity. Further-
more, restoring bile acid homeostasis by farnesoid X receptor activation markedly reduces
PTB and dramatically improves newborn survival rates. The findings thus establish an etio-
logic link between bile acids and PTB, and open an avenue for developing etiology-based
therapies to prevent or delay PTB.
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Preterm birth (PTB) is defined as babies born before37 weeks of pregnancy (gestation) and is the leading causeof perinatal mortality worldwide1,2. Surviving preterm
infants are also at risk for neurological, respiratory, and gastro-
intestinal complications; metabolic syndrome; and cardiovascular
disease3–5. The prevalence of PTB ranges from 5% to 18% glob-
ally6. In the United States, one out of ten newborns is delivered
preterm and the PTB rates exhibit an uptrend with unknown
reasons7.
The underlying mechanisms by which PTB is induced are
complex and multi-factorial8,9. Despite current research efforts,
our understanding on the underlying mechanisms for PTB
remains limited. As a consequence, current available interven-
tions for preventing PTB show inconsistent benefits10,11. Bile
acids are synthesized in the liver and their homeostasis is main-
tained through a tightly regulated enterohepatic circulation
mainly through the complex farnesoid X receptor (FXR) signaling
pathways12,13. Bile acids are recently recognized as signaling
molecules to regulate a variety of cellular and metabolic activ-
ities14–16. In the studies of pregnant women with intrahepatic
cholestasis of pregnancy (ICP), it is recognized that elevated bile
acids are associated with increased risk for PTB17–19. However, a
direct etiological link between bile acids and PTB has not been
established and it remains to be determined whether liver injury
itself or elevated bile acids as a result of liver injury induce PTB.
In this study, a hospital-based cohort study with pregnant
women is conducted. PTB rates and serum total bile acids
(sTBAs) are determined and their correlations are evaluated.
Using mouse models, PTB is successfully reproduced with liver
injuries or bile acid challenge alone. Furthermore, restoring bile
acid homeostasis by FXR activation markedly reduces PTB and
dramatically improves newborn survival. The findings establish a
direct etiological link between bile acids and PTB and open an
avenue for developing mechanism-based therapies to prevent or
delay PTB.
Results
Participant characteristics. Among the 36,755 pregnant women
enrolled in the study, 36,612 subjects were ethnic Han Chinese
women (99.61%), while 143 subjects were other ethnic minority
women (0.39%). Twenty-two thousand five hundred and seventy-
one women (61.41%) were primipara, while 14,184 women
(38.59%) were multipara. Among the multipara, 652 women had
a history of PTB, while 23 women had a history of stillbirth. The
patients diagnosed with ICP received ursodeoxycholic acid at a
dose of 15 mg kg−1 day−1 until delivery. The cervical length of
the subjects with PTB was not evaluated. The average gestation
age when PTB occurred was 34 ± 2.3 weeks. Most of the PTBs
occurred at the gestation ages between 33 and 36 weeks (n=
2496, 86.8%) with 55 subjects (1.9%) having PTB at gestation ages
<28 weeks and 324 women (11.3%) having PTB at gestation ages
28–32 weeks.
sTBA levels positively correlated with the rates of PTB. Among
36,755 pregnant women, 2875 subjects experienced PTB while
33,880 subjects had full-term birth (FTB). The sTBAs were sig-
nificantly increased from 4.68 ± 5.31 μM in FTB to 5.69 ± 12.45
μM in PTB subjects (p= 4.2 × 10−18) (Fig. 1a). When sTBAs
were elevated from <10 (n= 34,227) to 10–39.9 (n= 2362),
40–99.9 (n= 146), and ≥100 μM (n= 20), the rates of PTB were
significantly increased from 7.6% to 9.2% (relative risk (RR) 1.21,
95% confidence interval (CI) 1.05–1.39) (p= 0.0055), 29.5% (RR
3.87, 95% CI 2.86–5.23) (p= 5.3 × 10−24), and 50% (RR 6.57,
95% CI 3.53–12.22) (p= 9.6 × 10−14), respectively (Fig. 1b and
Supplementary Table 1). Correlation analysis confirmed that
sTBA concentrations directly correlated with the PTB rates (r=
0.988; p= 0.012; Fig. 1b).
PTB is clinically categorized into spontaneous (sPTB) and
iatrogenic (medically indicated) PTB (iPTB). Among the 2875
PTB subjects, 1302 had sPTB (45.3%) while 1573 had iPTB
(54.7%). Compared with FTB subjects, the sTBAs were
significantly elevated in subjects with sPTB (p= 0.0027) and
iPTB subjects (p= 2.6 × 10−22; Supplementary Fig. 1a). The sPTB
rates were significantly raised from 3.5% in subjects with <10 μM
sTBAs to 10.3% in subjects with sTBAs 40–99.9 μM (RR 2.9, 95%
CI 1.74–4.83; p= 0.0001) and to 20% in subjects with sTBAs
≥100 μM (RR 5.65, 95% CI 2.12–15.07; p= 0.005) (Supplemen-
tary Fig. 1b and Supplementary Table 1). Consistently, sTBA
levels positively correlated with the sPTB rates (r= 0.988, p=
0.007; Supplementary Fig. 1b). Similar to sPTB, the iPTB rates
significantly increased from 4.2% to 6.2% (RR 1.51, 95% CI
1.28–1.80; p= 7.6 × 10−8), 19.2% (RR 4.71, 95% CI 3.24–6.85;
p= 5.7 × 10−21), and 30% (RR 7.37, 95% CI 3.31–16.44; p=
4.7 × 10−10), respectively, when sTBA concentrations were
elevated from <10 to 10–39.9, 40–99.9, and ≥100 μM (Supple-
mentary Fig. 1c and Supplementary Table 1). sTBA levels were
also directly correlated with the iPTB rates (r= 0.978, p= 0.002;
Supplementary Fig. 1c).
Consistent with sTBA, aspartate aminotransferase (AST) levels,
which serve as the markers for liver injuries, were significantly
increased from 16.36 ± 14.70 U L−1 in FTB subjects to 20.35 ±
28.56 U L−1 in PTB subjects (p < 10−31; Fig. 1c). When AST levels
increased from 0–40 (n= 35,360) to 41–80 (n= 1046), 81–200
(n= 284), and >200 U L−1 (n= 65), the PTB rates were
significantly increased from 7.57% to 11.76% (p= 1.3 × 10−19),
19.37% (p < 10−31), and 30.77% (p= 1.8 × 10−12), respectively
(Fig. 1d). AST levels directly correlated with the PTB rates (r=
0.985, p= 0.015; Fig. 1d) and sTBA concentrations (Fig. 1e).
Consistently, serum AST levels were significantly increased in
subjects with sPTB (p= 1.7 × 10−5) and iPTB (p < 10−31) and
directly correlated with the rates of sPTB (r= 0.968, p= 0.032)
and iPTB (r= 0.964, p= 0.036) (Supplementary Fig. 1d–f). In
addition, a positive correlation was detected between serum AST
and sTBA levels in subjects with sPTB (r= 0.98, p= 0.02;
Supplementary Fig. 1g). However, no significant correlation was
detected between serum AST and TBA levels in subjects with
iPTB (r= 0.909, p= 0.091; Supplementary Fig. 1h).
Consistent with findings for AST, the PTB rates were
significantly increased when other liver injury markers were
elevated. As alanine aminotransferase (ALT) levels were
elevated from 0–40 to 41–80, 81–200, and >200 U L−1,
the PTB rates were increased from 8.8% to 9.6% (p= 0.25),
14.0% (p= 5 × 10−5), and 27.7% (p= 2.2 × 10−17), respectively
(Supplementary Fig. 1i). When total bilirubin (TBiL) concen-
trations were elevated from <17.1 to 17.2–34.2 μML−1, the PTB
rates remains unchanged. However, when TBiL concentrations
were further elevated to >34.3 μM L−1, the PTB rates were
markedly increased from 8.7% to 37.5% (p= 1.3 × 10−12;
Supplementary Fig. 1j). Similarly, as serum gamma-glutamyl
transpeptidase (GGT) levels elevated from <50 to 51–100 and
>100 U L−1, the PTB rates were significantly increased from
8.8% to 23.3% (p= 2.2 × 10−20) and 23.7% (p= 3.4 × 10−9),
respectively (Supplementary Fig. 1k).
Characteristics of pregnant women, sTBA levels, and PTB rates.
Among the characteristics of the subjects, maternal age20–23, and
pre-pregnancy body mass index (BMI)24–27 had significant impacts
on PTB. We performed correlation analyses between sTBA con-
centrations and PTB rates in subjects with different maternal ages
or pre-pregnancy BMIs.
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The subjects were divided into five age groups, 18–24, 25–29,
30–34, 35–39, and 40–50 years. Subjects at ages 25–29 years had
the largest population (n= 19,289) and the lowest PTB rate
(6.8%) (Fig. 2a and Supplementary Table 2). As the maternal age
advanced, the PTB rates increased from 6.8% to 8.6% (p= 2.4 ×
10−6), 11.5% (p= 2.9 × 10−15), and 20.1% (p= 6.1 × 10−21) in
the age groups 30–34 (n= 6122), 35–39 (n= 2025), and 40–50
(n= 319), respectively. The youngest age group (age 18–24, n=
9000) also had a significantly increased PTB rate (8.1%) (p=
1.3 × 10−4). sTBAs showed an uptrend as maternal age advanced
and directly correlated with the PTB rates among the five age
groups (r= 0.981, p= 0.003; Fig. 2b).
Based on the BMIs, the subjects were categorized into four
groups. Among the 36,755 pregnant women, 78.91% subjects had
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healthy body weight (BMI 18.5–24.9, n= 29,004) with the lowest
PTB rate of 7.1% (Fig. 2c). When pregnant women become
overweight (BMI 25–29.9, n= 4593) and obese (BMI ≥ 30, n=
185), the PTB rates were significantly increased to 11.9% (p=
8.9 × 10−31) and 14.6% (p= 7.9 × 10−5), respectively. On the
other hand, underweight subjects (BMI < 18.5, n= 2973) also had
a significantly increased PTB rate of 8.2% (p= 0.03). More
importantly, sTBAs exhibited an increased trend as BMI
increased and directly correlated with the PTB rates among the
four BMI groups (r= 0.949; p= 0.05).
Similar to sTBA, AST levels gradually increased as maternal
age advanced or BMI increased and positively correlated with the
PTB rates (r= 0.988, p= 0.002 or r= 0.966, p= 0.034, respec-
tively; Supplementary Fig. 2a, b). As expected, the AST and sTBA
levels were directly correlated among the five age groups (r=
0.983, p= 0.003) and four BMI groups (r= 0.976, p= 0.024)
(Supplementary Fig. 2c, d).
Liver disorders of pregnant women, sTBA levels, and PTB
rates. Among the 36,755 subjects, 1805 were diagnosed having
non-alcoholic fatty liver disease (NAFLD), a rate of 4.91%, while
505 were diagnosed having ICP, a rate of 1.37%. Compared with
the rate of 7.82% PTB in all the subjects, pregnant women with
NAFLD and ICP had significantly increased PTB rates, 13.96% (p
= 3.1 × 10−19) and 23.17% (p < 10−31), respectively (Fig. 3a). Such
increases in PTB rates correlated with elevated sTBA concentra-
tions in those subjects. The sTBA levels were significantly elevated
from 4.8 ± 5.3 μM in all subjects to 7.3 ± 13.3 μM in NAFLD
(p < 10−31) and 31.7 ± 24.4 μM in ICP subjects (p < 10−31)
(Fig. 3a). Among the subjects with NAFLD, the sTBA levels
were significantly higher in subjects with PTB (11.83 ± 22.01 μM,
n= 217) than those with FTB (6.53 ± 10.28 μM, n= 1337)
(p = 1.1 × 10−9; Fig. 3b). Similarly, among the pregnant women
with ICP, significantly higher sTBA levels were detected in PTB
subjects (42.92 ± 42.44 μM, n= 117) when compared to FTB
subjects (28.33 ± 24.37 μM, n= 388) (p= 3.6 × 10−6; Fig. 3b).
Similarly, the rates of both sPTB and iPTB were significantly
increased from 3.54% and 4.28% in all subjects to 5.47% (p=
6.18 × 10−6) and 8.49% (p= 3.0 × 10−16) in NAFLD subjects and
6.14% (p= 0.0018) and 17.03% (p < 10−31) in ICP subjects,
respectively (Supplementary Fig. 3a, b and Supplementary
Table 3). Correlatively, sTBAs were increased from 4.8 ± 5.3 μM
in all subjects to 11.6 ± 24.1 (p= 1.3 × 10−6) and 12.0 ± 20.7 μM
(p= 3.0 × 10−16) in subjects with sPTB and iPTB among the
NAFLD patients (Supplementary Fig. 3a, b). Similarly, sTBAs
were markedly elevated to 46.5 ± 44.4 (p < 10−31) and 41.6 ± 41.9
μM (p < 10−31) in subjects with sPTB and iPTB, respectively,
among the ICP patients (Supplementary Fig. 3a, b). Among the
NAFLD subjects, sTBAs were significantly higher in subjects with
sPTB (11.57 ± 24.06 μM, n= 85; p= 10−4) and iPTB (11.99 ±
20.68 μM, n= 132; p= 2.8 × 10−7) than in the FTB subjects (6.53
± 10.28 μM, n= 1337) (Supplementary Fig. 3c). Similarly, among
the subjects with ICP, sTBAs were significantly elevated from
28.33 ± 24.37 μM in FTB subjects (n= 388) to 46.54 ± 44.38 μM
in subjects with sPTB (n= 31; p= 2.0 × 10−4) and 41.62 ± 41.92
μM subjects with iPTB (n= 86; p= 10−4) (Supplementary
Fig. 3c).
Consistent with liver injuries and increased sTBA levels in
patients with NAFLD and ICP, serum AST levels were
significantly elevated from 16.67 ± 14.90 U L−1 in all the subjects
to 28.72 ± 35.45 U L−1 in NAFLD (p < 10−31) and 72.40 ± 85.31
U L−1 in ICP subjects (p < 10−31). Elevated AST levels correlated
with increased rates of PTB (Fig. 3c). Among the subjects with
NAFLD, AST levels were significantly increased in subjects with
PTB (44.23 ± 56.97 U L−1) when compared to those with FTB
(26.20 ± 34.51 U L−1) (p= 1.9 × 10−10; Fig. 3d). Similarly, higher
AST levels were detected in PTB subjects (83.16 ± 91.38 U L−1)
than those with FTB (69.15 ± 84.22 U L−1) among ICP patients
without reaching a statistical significance (p= 0.12; Fig. 3d).
Consistently, among the NAFLD subjects, AST levels were
significantly increased from 26.20 ± 34.51 U L−1 in FTB subjects
to 39.72 ± 53.44 U L−1 in sPTB (p= 7.8 × 10−4) and 47.13 ±
59.14 U L−1 in iPTB subjects (p= 10−9) (Supplementary Fig. 3d).
Similarly, among ICP subjects, serum AST levels were elevated in
subjects with sPTB (84.58 ± 90.34 U L−1) and iPTB (82.65 ±
92.27 U L−1) when compared to the FTB subjects (69.15 ± 84.22)
without reaching a statistical significance (Supplementary
Fig. 3d).
Estrogen induced cholestasis and PTB in pregnant mice. Pre-
vious investigations reported that elevated reproductive hor-
mones including estrogens during the late stage of pregnancy
contributed to the pathogenesis of ICP23–25. Indeed, estrogen-
induced cholestasis as animal models for ICP has been well
established in rodents26,27. However, no studies have been carried
out to investigate the effects of estrogen-induced cholestasis on
the outcome of pregnancy in rodent models. In this study, we
carried out experiments to determine whether estrogen-induced
cholestasis and bile acid dysregulation can reproduce the PTB
observed in ICP patients. As shown in Fig. 4a, treatment of
pregnant mice with synthetic estrogen 17α-ethynylestradiol (EE2)
starting at gestation day 16.3 significantly induced PTB. The
mean gestation days were significantly decreased from 19.9 ±
0.44 days in control mice (n= 9) to 18.76 ± 1.15 days in EE2-
treated mice (n= 12) (p= 0.013). Among the treated mice, 58.3%
gave PTB (earlier than 19.1 days) and a large portion of newborns
were dead with a huge variation from mouse to mouse (p=
0.0068). The rates of live birth ranged from 0% to 91.7% with an
average of 34.44 ± 29.78%, which is significantly lower than the
control (p= 0.0031; Fig. 4a). sTBAs were markedly elevated from
7.49 ± 2.01 μM in control to 31.91 ± 3.12 μM in treated mice
(p = 3.5 × 10−14) and negatively correlated with gestation days
(r =−0.647, p= 0.043) and the rates of live birth (r=−0.601,
p = 0.03) (Fig. 4b). As expected, AST levels were significantly
elevated from 17.3 ± 8.5 U L−1 in control to 87.3 ± 19.2 U L−1 in
treated mice (p= 5.9 × 10−9). The AST levels negatively
Fig. 1 Elevated sTBAs in pregnant women with PTB. a sTBA levels in pregnant women with FTB (n= 33,880) and PTB (n= 2875). Bar chart shows the
mean ± SD with small dots representing the data point distribution. b As sTBA levels elevated from <10 (n= 34,227) to 10–39.9 (n= 2362), 40–99.9 (n=
146) and ≥100 μM (n= 20), the PTB rates gradually increased. The PTB rates directly correlated with the sTBA concentrations. Data points in the lower
panel are presented as mean ± SD. c Serum AST levels in pregnant women with FTB (n= 33,880) and PTB (n= 2875). The box and whisker plots show the
maximum, minimum data points, median value, and 75th and 25th quartile. d Various AST levels of 0–40 (n= 35,360), 41–80 (n= 1046), 81–200 (n=
284), and >200U L−1 (n= 65) with corresponding PTB rates. The PTB rates directly correlated with AST levels. Data points in the lower panel are
presented as mean ± SD. e sTBA concentrations of <10 (n= 34,227), 10–39.9 (n= 2362), 40–99.9 (n= 146), and ≥100 μM (n= 20) directly correlated
with the AST levels. Data points are presented as mean ± SD. Student’s t test for pairwise comparison (two-sided) and one-way ANOVA, followed by
Tukey post hoc test were applied for statistical analysis. Pearson correlation analysis was applied to determine the correlation coefficient and associated
p values. Source data are provided as a Source Data file.
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correlated with the rates of live birth (r=−0.678, p= 0.015) but
not with gestation days (r= 0.143, p= 0.657) and the sTBA
concentrations (r= 0.135, p= 0.675) (Supplementary Fig. 4a). In
addition, no significant correlations were detected between the
rates of live birth and the gestation days (r=−0.177, p= 0.583;
Supplementary Fig. 4b).
Carbon tetrachloride (CCl4) induced liver injury and PTB in
pregnant mice. Currently, no animal models have been estab-
lished for studying PTB with liver injuries. In this study, we used
CCl4 as a challenging agent to induce liver injury and bile acid
dysregulation and investigate the effects on PTB in pregnant
mice. CCl4 is a hepatotoxic agent that is commonly used to
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induce various hepatic injuries, including NAFLD, fibrosis, and
non-alcoholic steatohepatitis.
As shown in Fig. 5a, CCl4 dose-dependently induced PTB. The
mean gestation days were significantly shortened from 19.8 ±
0.5 days in control (n= 9) to 18.9 ± 1.1 (p= 0.036), 18.1 ± 0.6 (p=
7.3 × 10−7), and 17.6 ± 0.5 days (p= 2.7 × 10−6) in mice treated
with 1 (n= 5), 1.5 (n= 9), and 2ml kg−1 CCl4 (n= 5), respectively.
Dosing of 1ml kg−1 CCl4 resulted in 60% PTB while 100% mice
gave PTB with the doses of 1.5 and 2ml kg−1 CCl4. The minimal
dose (1.5ml kg−1) that induced 100% PTB was used for subsequent
studies, and the mice in this group were further characterized. The
rates of live birth were markedly decreased to 26.63 ± 27.82% in
mice treated with 1.5ml kg−1 CCl4 (p= 0.0015; Fig. 5a). sTBAs
were significantly elevated from 7.49 ± 2.01 μM in control to
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27.78 ± 10.02 μM in treated mice (p= 1.7 × 10−5) and negatively
correlated with the gestation days (r=−0.867, p= 0.002) as well as
the rates of live birth (r=−0.848, p= 0.004) (Fig. 5b).
As expected, AST concentrations were markedly elevated from
17.3 ± 8.5 U L−1 in control to 122.1 ± 22.8 U L−1 in CCl4-treated
mice (p= 1.1 × 10−9) and positively correlated with sTBA levels
(r= 0.765, p= 0.016). However, no significant correlations were
detected between AST levels and the gestation days (r=−0.545,
p= 0.129) nor with the rates of live birth (r=−0.49, p= 0.181;
Supplementary Fig. 5a). It was noted that most of the dead
newborns were from the mice having extremely early PTB around
gestation day 17.5. Consistently, the rates of live birth positively
correlated with the gestation days (r= 0.967, p < 0.001; Supple-
mentary Fig. 5b).
Bile acid cholic acid (CA) induced PTB in pregnant mice. The
data from pregnant women and mice treated with EE2 or CCl4 all
demonstrated that sTBA levels positively correlated with the PTB
rates. We hypothesized that elevated serum bile acids directly
induced PTB. To test the hypothesis, pregnant mice were treated
with a diet containing 0.5% or 1% CA starting at gestation day
15.3. As shown in Fig. 6a, CA dose-dependently induced PTB.
The average gestation days were decreased from 19.9 ± 0.4 in the
control group (n= 9) to 19.4 ± 0.8 with a PTB rate of 50% in mice
fed with 0.5% CA diet (n= 8; p= 0.14) and 17.9 ± 0.3 with a PTB
rate of 100% in mice fed with 1% CA diet (n= 6; p= 5.1 × 10−7).
All the newborns were alive in mice fed with 0.5% CA diet while
on average 85.0 ± 10.6% of newborns were alive in the group fed
with 1% CA.
As expected, sTBA levels were significantly elevated in the two
treatment groups. The average sTBAs were increased from 7.49 ±
2.01 μM in control mice to 17.4 ± 3.3 μM in mice fed with 0.5%
CA diet (p= 2.7 × 10−6) and 24.9 ± 7.2 μM in mice fed with1%
CA diet (p= 1.5 × 10−5) (Fig. 6b). Correlation analysis revealed
that sTBAs negatively correlated with the gestation days
Fig. 3 Pregnant women with NAFLD and ICP had increased risk for PTB with elevated sTBAs. a The PTB rates, sTBA levels, and their correlations in all
subjects (n= 36,755) and the subjects with NAFLD (n= 1554) or ICP (n= 505). The box and whisker plots of the middle panel show the maximum,
minimum data points, median value, and 75th and 25th quartile. Data points for serum TBA are presented as mean ± SD in the right panel. b The sTBA
levels in the subjects with FTB (n= 1337 for NAFLD, n= 388 for ICP) and PTB (n= 217 for NAFLD, n= 117 for ICP) among the pregnant women with
NAFLD or ICP. The box and whisker plots show the maximum, minimum data points, median value, and 75th and 25th quartile. c Serum AST levels in all
subjects (n= 36,755) and subjects with NAFLD (n= 1554) or ICP (n= 505). The AST levels correlated with the rates of PTB. The box and whisker plots in
the left panel show the maximum, minimum data points, median value, and 75th and 25th quartile. The data points for AST levels are presented as mean ±
SD in the right panel. d The AST levels in subjects with FTB (n= 1337 for NAFLD and n= 388 for ICP) and PTB (n= 217 for NAFLD and n= 117 for ICP)
among the pregnant women with NAFLD or ICP. The box and whisker plots show the maximum, minimum data points, median value, and 75th and 25th
quartile. Student’s t test for pairwise comparison or one-way ANOVA, followed by Tukey post hoc test for multiple group comparison were applied for
statistical analysis. Source data are provided as a Source Data file.
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Fig. 4 EE2-induced liver injuries, bile acid dysregulation, and PTB in pregnant mice. a The gestation days, PTB rates, and rates of live birth in controls
(n= 9) and EE2-treated pregnant mice (n= 12). The data are presented as mean ± SD in the right and left panels. b The sTBA levels in controls (n= 9) and
EE2-treated mice (n= 12) and a negative correlation between sTBA concentrations and the gestation days or the rates of live birth. The means and
standard errors of the group values were indicated by the long and short lines, respectively. Student’s t test for pairwise comparison (two-sided), Chi-
squared test for proportion comparisons, and Pearson correlation analysis were applied for statistical analysis. Source data are provided as a Source
Data file.
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(r=−0.801, p= 0.001) and the rates of live birth (r=−0.803, p
= 0.001) (Fig. 6b).
Consistent with CA being a mild bile acid in inducing
hepatotoxicity, AST levels were only slightly increased from
17.3 ± 8.5 U L−1 in control to 22.8 ± 4.6 (p= 0.14) and 32.1 ± 7.9
U L−1 (p= 0.006) in CA-treated mice (Fig. 6c). It should be noted
that the AST levels among the three groups are all within the
normal physiological range for mice (from 10 to 45 U L−1),
indicating that minimal liver injury was induced by CA
treatment. Correlation analysis showed that AST levels negatively
correlated with gestation days (r=−0.835, p < 0.001) and the
rates of live birth (r=−0.892, p < 0.001; Supplementary Fig. 6a)
while positively correlated with sTBAs (r= 0.957, p < 0.001;
Supplementary Fig. 6a). A direct correlation between the
gestation days and rates of live birth was also detected (r=
0.774, p= 0.002; Supplementary Fig. 6b).
Elevated bile acids, not liver injury, induced PTB. As presented
above, 0.5% CA in diet induced 50% PTB with minimal liver
injury as AST levels did not differ from the controls. The data
indicated that it was the elevated bile acids, not liver injury, that
induced PTB. To further confirm such notion, we carried out
additional studies to elevate bile acid levels without inducing
liver injury. First, we treated the non-pregnant mice with a
reduced dose of CA (0.3%) or FXR antagonist DY268 to deter-
mine the effects of the treatments on sTBA and AST levels. It was
reasoned that FXR antagonism would increase endogenous bile
acid levels through increasing bile acid synthesis and reducing
bile acid disposition. As shown in Supplementary Fig. 7a, sTBA
levels were significantly elevated in mice treated with 0.3% CA in
diet (n= 7; p= 7.2 × 10−5) or DY268 (n= 7; p= 9.4 × 10−5)
when compared to the controls (n= 9). However, the AST levels
were comparable to the control group (p= 0.97 or p= 0.92;
Supplementary Fig. 7b), indicating that no liver injury was
induced by either of the treatments. The bile acid levels in mice
treated with 0.3% CA in diet or DY268 were elevated to 14.1 ±
2.6 or 13.7 ± 2.4 μM, which may not be high enough to effectively
induce PTB based on the findings with the treatment of 0.5% CA
in diet (Fig. 6a, b). Therefore, we treated pregnant mice with a
combination of 0.3% CA and DY268. As shown in Fig. 7a, the
average gestation days were significantly decreased from 19.9 ±
0.4 in the control group (n= 9) to 18.3 ± 0.3 in the treatment
groups (n= 8) (p= 2.1 × 10−5). A rate of 87.5% PTB (7 out of 8
mice) was reached in the pregnant mice treated with 0.3% CA
and DY268 (p= 4 × 10−4). As expected, sTBA levels were
markedly elevated to 22.3 ± 2.8 μM in the treatment group (p=
3.1 × 10−9; Fig. 7b), which is significantly higher than the sTBA
levels in mice treated with 0.3% CA or DY268 alone (Supple-
mentary Fig. 7a). On the other hand, AST levels were comparable
to the control group (p= 0.33; Fig. 7c). Histopathology exam-
ination confirmed no liver injury (Fig. 7d). Consistent with the
findings from pregnant mice treated with 0.5% (Fig. 6a), all the
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newborns were alive. The data thus firmly established that it was
the elevated bile acids, not liver injury itself, that induced PTB.
Prevention of PTB by restoring bile acid homeostasis. FXR is
the master regulator of bile acid homeostasis. Activation of FXR
by bile acids results in reduced bile acid synthesis and enhances
bile acid disposition28,29. We hypothesized that PTB should be
prevented by restoring bile acid homeostasis through FXR acti-
vation. To test the hypothesis, pregnant mice were treated with
CCl4 alone or a combination of CCl4 and a synthetic FXR agonist
GW 4064. As shown in Fig. 8a, GW4064 significantly increased
the gestation days from 17.9 ± 0.59 in mice treated with CCl4
(n = 9) to 19.1 ± 0.76 in mice treated with both CCl4 and
GW4064 (n= 13) (p= 9.6 × 10−4). The PTB rates were markedly
decreased from 100% to 38.5% (p= 0.04) and the rates of live
birth were dramatically improved from 25.6 ± 27.8% to 91.4 ±
20.9% (p= 0.0025). As expected, sTBAs were significantly
reduced from 38.3 ± 4.1 to 23.8 ± 5.5 μM (p= 2.4 × 10−6). Similar
to sTBA, AST levels were significantly decreased from 122.1 ±
22.8 to 43 ± 15.3 U L−1 (p= 3.7 × 10−8) and positively correlated
with sTBA concentrations (r= 0.928, p < 0.0001; Fig. 8b). sTBA
concentrations negatively correlated with the gestation days (r=
−0.775, p= 0.005) but not with the rates of live birth (Supple-
mentary Fig. 8a). Serum AST levels negatively correlated with
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both the gestation days (r=−0.725, p= 0.012) and the rates of
live birth (r=−0.66, p= 0.038; Supplementary Fig. 8b). A direct
correlation between the gestation days and the rates of live birth
was also detected (r= 0.648, p= 0.043; Supplementary Fig. 8c).
As the transporter responsible for the rate-limiting biliary
secretion of bile acids in the enterohepatic circulation, the
expression of bile salt export pump (Bsep) was significantly
upregulated by GW4064 (p= 0.0031; Fig. 8c), indicating
enhanced biliary bile acid disposition. On the other hand,
cholesterol 7α-hydroxylase (Cyp7a1), a rate-limiting enzyme for
bile acid synthesis, was significantly downregulated (p= 0.0092),
suggesting reduced bile acid synthesis. Consistently, the
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Fig. 7 Elevated bile acids, not liver injury, induced PTB. a The gestation days and PTB rates in control (n= 9) and mice treated with a combination of
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treated with a combination of CA and DY268 (n= 8). d Representative hepatic histopathology of control and mice treated with CA and DY267. Consistent
results were obtained from the control (n= 8) and treated mice (n= 8). Student’s t test for pairwise comparison (two-sided) and Chi-squared test for
proportion comparisons were applied for statistical analysis. Source data are provided as a Source Data file.
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expression of small heterodimer partner (Shp), a repressor for
Cyp7a1 expression, was significantly increased (p= 0.012). On
the other hand, GW4064 treatment had limited effects on Fxr
expression (p= 0.34; Fig. 8c).
Discussion
The underlying mechanisms by which PTB is induced are com-
plex and multi-factorial8,9. Bile acids are recently recognized as
signaling molecules to regulate a variety of cellular and metabolic
activities14–16. In an early study to investigate the effects of bile
acids on the fetus complications, direct intravenous infusion of
CA into fetal lambs resulted in early delivery30. However, the
cause of premature labor in the ewes with fetuses infused with CA
was not evident. In this study, we found that sTBA concentrations
in the pregnant women were directly correlated with the rates of
PTB including sPTB and iPTB regardless of the characteristics of
the pregnant women, such as maternal age and BMI or the
etiologies of liver injuries, such as NAFLD and ICP. Our data are
in line with the findings from previous reports that sTBA levels
were correlated with the risks for PTB in ICP patients17–19. In this
study, we further demonstrated that bile acid CA effectively and
dose-dependently induced PTB in pregnant mice. The findings
thus etiologically link elevated bile acids to PTB. Consistent with
our finding, myometrium isolated from pregnant women with
ICP was more sensitive to oxytocin than the myometrium from
normal pregnant women, which may be due to the upregulation
of oxytocin receptor expression in myometrium by bile acids31,32.
Therefore, dysregulation of bile acids due to liver disorders or
other pathological conditions is a previously unrecognized risk
factor for PTB. sTBA concentrations may represent a potential
predictive marker for PTB.
The liver is the organ responsible for nutritional and energy
metabolism. As a physiological adaption, liver size is significantly
enlarged during the late stage of pregnancy to meet the nutri-
tional and metabolic demands of the mother and growing
fetus33–35. Under pathological conditions with dysregulated bile
acids due to liver diseases or others, elevated bile acids may act as
a message of compromised liver to communicate with and reg-
ulate other organs of the body. When the energy demands from
the growing fetus and mother cannot be met by the compro-
mised liver, termination of the pregnancy may become the
option for the mother to survive. Therefore, early termination of
pregnancy or PTB may be considered as a protective or adaptive
mechanism for a pregnant woman to survive when liver function
is compromised36,37. Consistently, similar to sTBA, serum AST,
ALT, TBiL and GGT levels, which commonly serve as liver
function or damage markers, directly correlated with the PTB
rates in both human (Figs. 1d and 3c, Supplementary Figs. 1e, f
and 2a, c) and mice (Supplementary Figs. 4a, 5a, 6a, and 8b). In
addition, pregnant women with various liver disorders have
increased risk for PTB17–19,38–45.
Advanced maternal age and being overweight/obese have been
associated with increased risk for PTB20–27. However, the
underlying mechanisms are unknown. In this study, we found
that sTBA concentrations were gradually elevated as the maternal
age advanced (Fig. 2b) and BMI increased (Fig. 2d). More
importantly, positive correlations between elevated sTBAs and
increased PTB rates were detected in subjects with advanced
maternal age and overweight or obese (Fig. 2b, d). Therefore,
elevated circulating bile acids may directly contribute to the
increased risk for PTB in those subjects. Consistent with our
finding, previous clinical studies with non-pregnant subjects
showed that serum bile acids were significantly elevated in obese
subjects46–48. Currently, advanced age and overweight/obesity in
reproductive women are on the rise, which may contribute to the
current uptrend of PTB rate7. Modulating bile acid homeostasis
may be of clinical significance for reducing PTB in age-advanced
and overweight/obese subjects.
Among the liver disorders, NAFLD is considered the most
common disease49–51. Indeed, NAFLD is the commonest cause
for liver dysfunction in our study cohort, with 4.2% of the
pregnant women being diagnosed with NAFLD. Similar to the
subjects with ICP in this study and previous reports17–19, NAFLD
patients also had increased PTB rates (Fig. 3a). The finding is
consistent with a previous study reporting that the risk for PTB
increased 2.5-fold in subjects with NAFLD42. However, the
underlying mechanism is largely unknown. In this study, we
found that sTBAs were also significantly elevated in NAFLD
subjects (Fig. 3a) and thus may contribute to the induction of
PTB in NAFLD subjects. Dysregulation of bile acids in subjects
with NAFLD has long been recognized in non-pregnant subjects.
A large body of evidence from clinical as well as preclinical stu-
dies demonstrate that sTBA concentrations were largely elevated
in subjects with NAFLD52. Restoring bile acid homeostasis may
represent a strategy to reduce the risk for PTB in pregnant
women with NAFLD and ICP.
Elevated estrogens during late stages of pregnancy play an
important role in the pathogenesis of ICP53–55. On the other
hand, CCl4 has been widely used to induce various hepatic
injuries in animals, including NAFLD, fibrosis, and non-alcoholic
steatohepatitis56–58. In this study, we successfully reproduced
PTB in pregnant mice with liver injuries induced by EE2 or CCl4.
It was noted that high percentages of the newborns were dead in
both EE2- and CCl4-induced PTB models. However, the under-
lying mechanisms may differ. In the CCl4 model, the rates of live
birth negatively correlated with the gestation days (Supplemen-
tary Fig. 5b) with majority of dead births from the pregnant mice
with extremely early gestation days (17.5 days). The finding is
consistent with higher fetal mortality rates in pregnant women
with extreme early PTB59,60. However, in the EE2 model, the
rates of live birth did not directly correlate with the gestation days
(Supplementary Fig. 4b), indicating that estrogen-induced cho-
lestasis may have direct adverse effects on the fetuses. In patients
with ICP, a high percentage of PTB is iatrogenic (73.5%; Sup-
plementary Fig. 3a, b), which are mainly due to fetal stresses and
complications. In addition, increased stillbirths were also reported
in pregnant women with ICP17–19. The high rates of dead births
observed in the EE2 model may represent the sum of iPTB and
stillbirth in pregnant women with ICP. It should be noted that the
high dose of EE2 (25 mg kg−1) used in this study may also
contribute to the high rates of dead birth. Taken together, EE2-
induced PTB may represent a good mouse model to study the
pathogenesis of iPTB and stillbirth in pregnant women with ICP,
while CCl4-induced PTB may represent a good mouse model to
study PTB associated with liver disorders or dysregulation of bile
acids other than ICP.
In this study, bile acid CA induced PTB as effectively as, if not
more effectively than, EE2 and CCl4 treatments (Figs. 4a, 5a, 6a,
and 7a). Consistent with CA being a mild bile acid in inducing
hepatotoxicity61, minimal or no liver injury was detected in mice
treated with 0.5% CA or a combination of 0.3% CA and FXR
antagonist DY268 as the AST levels were comparable to the
control group (Figs. 6c and 7c) and histopathology examination
revealed no hepatic toxicity (Fig. 7d). The data thus demonstrate
that it is the elevated bile acids, not liver injury itself, that induces
PTB. Distinct from the EE2, CCl4 and other reported PTB mouse
models62, which have low rates of live birth (34.4 ± 29.8 for EE2
and 25.6 ± 28.7 for CCl4 model), majority of the newborns from
CA-induced PTB were alive with a rate of live birth 85.0 ± 10.6%,
100%, and 100% in mice treated with 1% CA, 0.5% CA, and
a combination of 0.3% CA and DY268, respectively. Therefore,
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CA-induced PTB represents a good model for studying the
developmental consequences of the newborns. In addition, the
findings also indicate that elevated bile acids are the trigger for
inducing PTB while liver injuries induced by EE2, CCl4, or other
factors may contribute to the low rates of live birth. Therefore,
sTBA can potentially serve as a better marker for predicting PTB
while other liver injury tests, such as AST, can potentially serve as
better predictors for the health status of the fetus. Our findings
indicated that reducing bile acids potentially prevent or delay
PTB while promoting liver repairing or improving liver function
may increase the survival rate of the newborns in pregnant
women with liver disorders, including cholestasis. Considering
the fact that some subjects had elevated bile acids but were
protected from PTB, other factors such as individual variations in
signaling pathways that mediate bile acid-induced PTB exist and
remain to be identified.
Current interventions for preventing or delaying PTB did not
achieve consistent improvement10,11. New mechanism-based
interventions are in need. In this study, we demonstrated that
restoring the bile acid homeostasis by FXR activation significantly
reduced CCl4-induced PTB and dramatically improved the sur-
vival rates of the newborns. The finding holds a great promise for
developing new therapies to prevent or delay PTB for pregnant
women at high risk for PTB with dysregulated bile acids due to
liver disorders or other conditions.
Methods
Study cohort. A prospective cohort was recruited at the Nantong Maternal and
Child Health Hospital (NMCH) affiliated to Nantong University, China. The
medical history and supporting clinical and laboratory information were collected
at baseline. All pregnant women aged 18–50 years were screened. Exclusion criteria
were described previously41. Data on maternal demographic characteristics were
collected from questionnaires completed by women at the first antenatal visit41. A
total of 44,906 pregnant women were screened during their first trimester of
pregnancy at the NMCH. Of these, 6242 were excluded owing to: multiple preg-
nancy in 1518 subjects, other infection in 2496 subjects, concurrent medical
complications (diabetes, hypertension, or heart diseases) in 841 subjects, and
spontaneous or induced abortion in 2787 subjects. Thereafter, 37,264 pregnant
women were recruited in this study. Most of the enrolled subjects received at least
three health examinations and were followed up until delivery. Five hundred and
nine subjects were excluded because of lost to follow-up (292 subjects) or
incomplete data (217 subjects). Finally, after exlusion, a total of 36,755 pregnant
women were included in the study. We tried to include as many participants as
possible and did not exclude participants if they fulfilled the inclusion criteria and
follow-up. Self-selection bias was prevented by the blinding of investigators who
collected the data and those who analyzed the data. Diagnoses of NAFLD and ICP
were made according to relevant guidelines63,64. The primary outcome was PTB
defined as earlier than 37 weeks of gestation. The PTB was further categorized into
spontaneous (either following onset of contractions or spontaneously ruptured
membranes) and iatrogenic (medically indicated labor due to maternal or fetal
reasons) PTB65. The cohort study was performed according to the Declaration of
Helsinki and approved by the Institutional Review Board of NMCH. Written
informed consents were obtained from all participants. The study was retro-
spectively registered to the Research Registry (https://www.researchregistry.com/)
with an identification number 5434.
Chemicals and reagents. CA, CCl4, GW4064, olive oil, and EE2 were purchased
from Sigma-Aldrich. 1,2-Propanediol and corn oil were purchased from Acros
Organics. Mouse TBA kits were purchased from Crystal Chem. Mouse AST Kit was
purchased from Biovision.
Mouse models for PTB with liver injuries. Timed pregnancy of CD-1 mice was
achieved by mating overnight. Next day when the male mice were removed is
considered gestation day 0. EE2 was administered subcutaneously once daily at a
dose of 25 mg kg−1 in a solution of 80% 1,2-propanediol and 0.15% NaCl on
gestation day 16.3. The treatment was continued until labor. Single injection of
CCl4 was administered intraperitoneally at a dose of 1, 1.5, or 2 ml kg−1 in olive oil
(40% v/v) on gestation day 16.3. Upon initiation of the treatment, pregnant mice
were closely monitored for labor. The rates of live birth were recorded. The mice
were euthanized after the labor, and blood and tissues samples were collected for
analyses. All the mouse studies were approved by the Institutional Animal Care
and Use Committee of the University of Rhode Island. All mice were housed in
ventilated cages in a 12-h light–dark cycle (starting at 6:00 a.m. and 6:00 p.m.), with
controlled room temperature (20–22 °C) and relative humidity (40%). Mice had
access to food and water ad libitum.
Treatment of pregnant mice with bile acid CA and FXR antagonist DY268.
Treatment with 0.5% (w/w) or 1% CA in a regular chow diet was initiated at
gestation day 15.3 and continued until labor. Treatment with a combination of
0.3% CA (in diet) and FXR antagonist DY268 (20 mg kg−1, oral gavage, twice a
day) was also initiated at gestation day 15.3 and continued until labor. Pregnant
mice were closely monitored for labor after initiation of the treatment. The rates of
live birth were recorded. The mice were euthanized after the labor. Blood and
tissues samples were collected for analyses. For the study with non-pregnant mice,
mice were treated with 0.3% CA in diet or DY268 (20 mg kg−1, oral gavage, twice a
day) for 3 days. At the end of the study, mice were euthanized, and blood samples
were collected for sTBA and AST analyses.
Treatment of pregnant mice with a combination of CCl4 and FXR agonist
GW4064. Pregnant mice were treated with FXR agonist GW4064 on gestation day
15.3 through oral gavage twice a day with a dose of 50 mg kg−1 in corn oil and the
treatment continued till labor. Twenty-four hours after the first treatment of
GW4064, the pregnant mice were treated with CCl4 at a dose of 1.5 ml kg−1 in 40%
olive oil through intraperitoneal injection at gestation day 16.3. The mice were
closely monitored for labor after CCl4 treatment. The gestation days and rates of
live birth were recorded. The mice were euthanized after the labor. Blood and
tissues samples were collected for analyses.
TaqMan quantitative real-time PCR. Total RNA was isolated with RNA-Bee
regent (Tel-Test, Friendswood, TX). cDNA was synthesized with 1 μg of total RNA
and random primers in a total volume of 25 μl. The reactions were incubated
initially at 25 °C for 10 min and then at 50 °C for 50 min, followed by inactivation
of the reaction at 70 °C for 10 min. The cDNAs were then diluted five times with
water and subjected to real-time PCR using TaqMan Gene Expression Assay
(Applied Biosystems, Foster City, CA). The real-time PCR was performed using
TaqMan Universal PCR Master Mix (Applied Biosystems) in a total volume of 20
μl containing 10 μl of universal PCR master mix, 1 μl of gene-specific TaqMan
assay mixture, and 5 μl of cDNA templates. Cycling profile was 50 °C for 2 min, 95
°C for 10 min, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C, as
recommended by the manufacturer. Amplification and quantification were done
with the Applied Biosystems 7500 Real-Time PCR System. The TaqMan assay
probes for Fxr (assay ID: Mm00436425_m1), Shp (assay ID: Mm00442278_m1),
Cyp7a1 (assay ID: Mm00484150_m1), Bsep (assay ID: Mm00445168_m1), and
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) (assay ID: Mm99999915_g1)
were purchased from Applied Biosystems. Transcript levels of Fxr, Shp, Cyp7a1,
and Bsep were normalized against the GAPDH levels. Validated TaqMan PCR
probes and master mixtures were obtained from Applied Biosystems.
Liver function tests. All recruited pregnant women had baseline liver function
tests performed at the first antenatal visit at gestation weeks 12–14, followed by at
least one subsequent testing at gestation weeks 24–28. Additional testing was
requested as clinically appropriate at gestation weeks 32–36. Serum samples were
collected from pregnant women after fasting for at least 8 h. sTBA, AST, ALT,
GGT, and TBiL levels were measured using an automatic biochemical analyzer
(AU2700, Olympus, Japan). The highest values among the 2–3 tests for each
individual subjects were used for the data analyses. Mouse sTBAs were quantified
with the mouse TBA Kit from Crystal Chem. Mouse AST assays were carried out
with the Mouse AST Kit from Biovision.
Histopathology. Fresh liver tissues were collected and fixed with 10% formalin
immediately after euthanization of the mice. After fixation in 10% formalin solu-
tion for at least 24 h, the liver tissue samples were delivered to the Molecular
Pathology Core at Brown University for paraffin embedding, sectioning, hema-
toxylin and eosin staining, and histopathology examination by a pathologist. The
samples were randomized and blinded when they were delivered to the core. After
the histopathology report was provided to us, we decoded the samples and pre-
sented the data.
Statistics. Student’s t test was applied to pairwise comparison for normally dis-
tributed data. One-way analysis of variance was applied to analyze data with
multiple groups, followed by Tukey post hoc test for multiple comparisons. Chi-
squared test was applied for proportion comparisons. Pearson correlation analysis
was applied to determine the correlation coefficient (r) and associated p values.
Poisson regression model was used to estimate the RR with 95% CI. A p value of
≤0.05 was considered statistically significant. IBM SPSS Statistics 25, SAS, and
Prism version 8 GraphPad software were used for statistical analyses.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
All the relevant data that support the findings of this study are available from the
corresponding author upon request. The source data underlying Figs. 1a–e, 2a–d, 3a–d,
4a, b, 5a, b, 6a–c, 7a–c, 8a–c and Supplementary Figs. 1a–k, 2a–d, 3a–d, 4a, b, 5a, b, 6a, b,
7a, b, 8a–c are provided as a Source Data file.
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